Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID

Reuters09-23

Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID

Tevogen Bio Holdings Inc. has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533437-en) on September 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2569225790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569225790","market":"nz","top_or_hot":-1,"title":"Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVGNW\">Tevogen Bio Holdings Inc.</a> has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TVGN\">Tevogen Bio Holdings</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533437-en) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-23 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TVGNW\">Tevogen Bio Holdings Inc.</a> has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/TVGN\">Tevogen Bio Holdings</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533437-en) on September 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210150020.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL1yLyzs:1","article_id":"2569225790","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569225790","pubTimestamp":1758630629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tevogen Bio Holdings Inc. has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","TVGN":"Tevogen Bio Holdings","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Tevogen Bio宣布TVGN 489在针对与新冠后遗症病相关的持续性病毒库方面取得了有希望的结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"TVGN":0.9},"content_text":"Tevogen Bio Announces Promising Results for TVGN 489 in Targeting Persistent Viral Reservoirs Linked to Long COVID\n    \n\nTevogen Bio Holdings Inc. has announced the potential role of its investigational precision T cell therapy, TVGN 489, in addressing Long COVID, a condition affecting an estimated 20 million Americans. Emerging scientific evidence suggests that persistent viral reservoirs contribute to Long COVID, and TVGN 489 is designed to target virus-infected cells by focusing on multiple SARS-CoV-2 proteins across the viral genome. In a proof-of-concept clinical trial, TVGN 489 demonstrated efficacy in reducing viral load and showed persistence for at least six months without interfering with patients' immune responses. The company is preparing for clinical manufacturing of TVGN 489, with ongoing research to further explore its potential in restoring homeostasis in patients with Long COVID.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533437-en) on September 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569225790","isCrawlerRequest":true}